Highlights from ERS 2019

It is that time of the year!

Thousands of healthcare professionals are gathering in Madrid, Spain, where one of the most popular scientific events in the field of respiratory medicine - the ERS congress - is taking place.

For those of you who may not have the chance to attend in person and benefit from the rich exchange of information, Boehringer Ingelheim and Univadis are joining forces to bring you the latest news and expert opinions in "real time".

Scroll down to access news articles and podcast sessions featuring some of the leading experts in respiratory medicine, who would like to share their ERS experience with you.

Come back every day for more!

Independent coverage by

on Univadis

ERS 2019 – New recommendations and priorities for asthma management

Four speeches focused on providing an update on the GINA 2019 strategy report, including mechanisms underlying the adverse effects of β2-agonists, prevention of exacerbations in mild-asthma, the evidence of gaps in paediatrics and the management of severe asthma in adults.

on Univadis

ERS 2019 - Prevention and management of respiratory infections in primary care.

Respiratory infections are an important health problem in the primary care area. This session has covered different aspects on this issue.

on Univadis

ERS 2019 – ALERT: Abstracts leading to evolution in respiratory medicine trials: COPD and cough

This session, relating to clinical trials on COPD and cough, has included four late-breaking abstracts covering different topics: the identification of COPD patients who can benefit from benralizumab, the use of rheoplasty to relieve mucus production, the use of tele-rehabilitation in COPD and the efficacy of a new drug to treat refractory chronic cough.

Listen to daily podcast Boehringer Ingelheim

ERS Congress 2019: Day Four

The future may be digital in ILD, pulmonary rehabilitation may be for more patients than first thought, plus why air pollution is likely to be on the respiratory agenda for the foreseeable future... All topics included in today's podcast highlights from the 2019 European Respiratory Society Congress, with discussions hosted by Doctor Mariel Slater, medical advisor at Boehringer Ingelheim.

Today's guests:
Doctor Frits Franssen, pulmonologist based in Maastricht, Holland with a field of interest in COPD and pulmonary rehabilitation.
Doctor Claudia Valenzuela, pulmonologist and specialist in ILD, based in the Hospital La Princesa Comunidad de Madrid.
Professor David Halpin, pulmonologist with an interest in asthma and COPD, based in the UK.

Please note: This is educational content intended for healthcare professionals. The opinions expressed are those of the experts, not of Boehringer Ingelheim.

ERS Congress 2019: Day Three

Updates on progressive fibrosing ILD, cryobiopsy and e-cigarettes risks - all highlights of day three at the European Respiratory Society congress. Hosted by Doctor Mariel Slater, medical advisor at Boehringer Ingelheim.

Today's guests:
Professor David Halpin, pulmonologist with an interest in asthma and COPD, based in the UK.
Professor Michael Kreuter, pulmonologist from the University of Heidelberg in Germany.

Please note: This is educational content intended for healthcare professionals. The opinions expressed are those of the experts, not of Boehringer Ingelheim.

ERS Congress 2019: Day Two

Is personalised medicine the future for respiratory treatment? That's one of many topics on lung experts minds during this year's European Respiratory Society congress in Madrid.

Doctor Mariel Slater, Medical Insider podcast host and Boehringer Ingelheim advisor, discovers key learnings from the day's sessions.

Today's guests:
Doctor Richard Russell, consultant physician with Southern Health in the UK and a senior clinical researcher for the University of Oxford.
Professor Vincent Cottin from the Claude Bernard University of Lyon in France with a special interest in interstitial lung disease, particularly fibrosis.

Please note: This is educational content intended for healthcare professionals. The opinions expressed are those of the experts, not of Boehringer Ingelheim.

ERS congress view by the experts Boehringer Ingelheim

ILD highlights from the ERS international congress 2019

Recent updates for the treatment of interstitial lung disease (ILD) were presented and discussed at the 2019 European Respiratory Society (ERS) annual congress, including analyses from the COLDICE study, the RELIEF trial, the INBUILD trial, and the SENSCIS trial. The objective of this report is to provide healthcare professionals with highlights from the presentations that are most relevant to their daily practice.

Download this congress report to get up to date treatment information on idiopathic pulmonary fibrosis, progressive fibrosing ILD, and systemic sclerosis-associated ILD

Download

New directions in COPD

At the 2019 European Respiratory Society (ERS) annual congress held in Madrid, Spain, from 28 September – 2 October, new concepts were presented and discussed, including: advancements in pharmacologic treatments, the appropriate use of ICS therapy, treatment of exacerbations, as well as new insights on pulmonary rehabilitation, exercise capacity in patients with COPD and co-morbidities of COPD.

The objectives of this report are to inform interested healthcare professionals about the main COPD topics of discussion and highlights from the ERS 2019 and provide expert viewpoints on the clinical relevance of the new data for daily practice.

Download the Congress Report and get up to date on symptoms and treatment, exacerbations, role of eosinophils in guiding therapy, inhalers and inhalation, physical activity, and co-morbidities.

Download

Videos Boehringer Ingelheim

Dr Nazia Chaudhuri explains the progressive fibrosing ILD phenotype.

Symposium - Prof Sinthia Bosnic-Anticevich

See what Vincent Cottin, Professor of Respiratory Medicine, has to say about the threat of pulmonary fibrosis across a range of ILDs.

Prof Eric D. Bateman - BI Industry Symposium at ERS Congress 2018

See what Professor Toby Maher has to say in relation to this question.

Interstitial Lung Disease (ILD) encompasses a wide variety of chronic lung diseases such as IPF and SSc-ILD. A proportion of patients with ILD, develop a progressive fibrosing phenotype. Watch to see the destructive process of pulmonary fibrosis.

Prof. Richeldi and Prof. Maher discuss the consequences of a watch and wait approach in IPF and the risks involved.

Prof. Maher and Prof. Richeldi discuss the changes in the ATS/ERS/JRS/ALAT guidelines and its impact on clinical practice. They discuss the changes in IPF diagnosis and the possibility of expanding the number of patients to be diagnosed as IPF.

Alex's inspiring story depicts her life with scleroderma from early symptoms through to long-term acceptance. For support and guidance during your patient's journey, further information and resources are available at MoreThanScleroderma.com.

Progressive Fibrosing ILD Phenotype

Dr Nazia Chaudhuri explains the progressive fibrosing ILD phenotype.

Priorities and preferences: Does inhaler choice make a difference?

Symposium - Prof Sinthia Bosnic-Anticevich

The Threat of Pulmonary Fibrosis across a range of ILDs

See what Vincent Cottin, Professor of Respiratory Medicine, has to say about the threat of pulmonary fibrosis across a range of ILDs.

Podcast of the day

ERS Congress 2019: Day Four

Please note: This is educational content intended for healthcare professionals. The opinions expressed are those of the experts, not of Boehringer Ingelheim.

ACCESS ADDITIONAL RESOURCES FROM BOEHRINGER INGELHEIM

Asthma

GEMA Interactive Guideline (in Spanish) Access our interactive summary of the Spanish GEMA guidelines on Asthma
Mind the gap : Anticholinergic therapy in patients with moderate to severe asthma Webcast on the new perspectives on the management of pediatric and adult patients with moderate and severe asthma, with Prof. Harrisson, Prof. Vogelberg and Dr. Román-Rodriguez.

COPD

Respiratory webinar platform Here you will find scheduled online medical education events that are broadcast live direct to your screen

Pulmonary Fibrosis

Life with pulmonary fibrosis This website will support people living with pulmonary fibrosis to learn more about the condition and to connect them with resources to help.
Pulmonary Fibrosis 360 Discover how to monitor patients with ILDs and CTDs at risk of developing pulmonary fibrosis. Explore our resources on how HRCT can help in the diagnosis.

The content in this section is completely independent and is in no way affiliated with or coordinated by the European Respiratory Society (ERS).

Highlights from ERS 2019

Independent coverage by

ERS 2019 – New recommendations and priorities for asthma management

ERS 2019 - Prevention and management of respiratory infections in primary care.

ERS 2019 – ALERT: Abstracts leading to evolution in respiratory medicine trials: COPD and cough

Sponsored content Boehringer Ingelheim

INBUILD® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases(1)

Listen to daily podcast Boehringer Ingelheim

ERS Congress 2019: Day Four

ERS Congress 2019: Day Three

ERS Congress 2019: Day Two

ERS congress view by the experts Boehringer Ingelheim

ILD highlights from the ERS international congress 2019

New directions in COPD

Videos Boehringer Ingelheim

Dr Nazia Chaudhuri explains the progressive fibrosing ILD phenotype.

Symposium - Prof Sinthia Bosnic-Anticevich

See what Vincent Cottin, Professor of Respiratory Medicine, has to say about the threat of pulmonary fibrosis across a range of ILDs.

Prof Eric D. Bateman - BI Industry Symposium at ERS Congress 2018

See what Professor Toby Maher has to say in relation to this question.

Interstitial Lung Disease (ILD) encompasses a wide variety of chronic lung diseases such as IPF and SSc-ILD. A proportion of patients with ILD, develop a progressive fibrosing phenotype. Watch to see the destructive process of pulmonary fibrosis.

Prof. Richeldi and Prof. Maher discuss the consequences of a watch and wait approach in IPF and the risks involved.

Prof. Maher and Prof. Richeldi discuss the changes in the ATS/ERS/JRS/ALAT guidelines and its impact on clinical practice. They discuss the changes in IPF diagnosis and the possibility of expanding the number of patients to be diagnosed as IPF.

Alex's inspiring story depicts her life with scleroderma from early symptoms through to long-term acceptance. For support and guidance during your patient's journey, further information and resources are available at MoreThanScleroderma.com.

Progressive Fibrosing ILD Phenotype

Priorities and preferences: Does inhaler choice make a difference?

The Threat of Pulmonary Fibrosis across a range of ILDs

ERS Congress 2019: Day Four

ACCESS ADDITIONAL RESOURCES FROM BOEHRINGER INGELHEIM

Asthma

COPD

Pulmonary Fibrosis